Fine tuning cardiac ablation could lead to quicker results for patients with arrhythmias

University of Michigan heart researchers are shedding light on a new method for steadying an abnormal heart rhythm.
Irregular heart rhythms, or arrhythmias, set the stage for a common, debilitating disorder called atrial fibrillation that puts adults as young as age 40 at risk for fatigue, fainting, cardiac arrest, and even death.
Medications can help, but doctors also use catheter ablation in which electrical impulses are delivered to a region of the heart to disrupt the arrhythmia.
However, half of patients require more than one ablation to see results. In a laboratory study, the U-M used photodynamic therapy, a technique long used in cancer research, to disrupt the specific cells causing the arrhythmia.
The study suggests cell-specific cardiac ablation could help patients avoid complications, and get closer to an arrhythmia-free life without having to undergo repeat hospital visits.
Chemists in the U-M Department of Chemistry and electrophysiologists at the U-M Center for Arrhythmia Research collaborated on the study that will require further examination before it is available in the hospital setting.
‘This cell-selective therapy may represent an innovative concept to overcome some of the current limitations of cardiac ablation,’ says lead study author Uma Mahesh Avula, M.D., research fellow at the U-M Center for Arrhythmia Research.
The heart consists of different types of cells such as myocytes, fibroblast, adiopocytes and purkinje fibres, which are all needed for normal cardiac activity.
The new study is the first of its kind to use photodynamic therapy and nanotechnology to ablate only the cardiac myocytes responsible for arrhythmias. In current ablative techniques, all cardiac cells receive ablative energy, which can lead to complications such as puncturing the heart muscle, bleeding or stroke.
‘Current ablation techniques are severely limited by its non-specific nature of cellular damage. Besides this lack of cellular discrimination markedly increases the required energy amounts and prolongs procedure times, all of which reduces overall ablation results,’ Avula says.
Catheter ablation has emerged as an important treatment option that requires careful assessment, planning and execution for optimal success rates. Advances over the past 20 years have made the treatment safer, but it remains highly complex.
‘Approaches that could simplify and shorten the procedure may contribute to more patients being treated,’ Avula says.
Rather than radiofrequency energy, the most common type used in cardiac ablation, the U-M team introduces the use of PDT in cardiac electrophysiology to target specific cell types. Targeted PDT, which was pioneered in the labs of study senior author U-M chemist and engineer Raoul Kopelman, Ph.D., is extensively used in cancer research for selectively killing cancerous cells.
The disruption induced by PDT is confined to cells that have been photosensitised, while adjacent non-photosensitised cells are unaffected. The U-M has applied for a patent for this technology.
‘We think this approach will decrease the extent of unwanted cell injury, inflammation, and ablation-related tissue damage, and pave a way for the development of more effective therapies for cardiac arrhythmias,’ says study senior author J